<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLURBIPROFEN SODIUM</span><br/>(flure-bi'proe-fen)<br/><span class="topboxtradename">Ansaid, </span><span class="topboxtradename">Ocufen<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic</span>; <span class="classification">nsaid</span>; <span class="classification">cox 1</span>; <span class="classification">antipyretic</span><br/><b>Prototype: </b>Ibuprofen<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg tablets; 0.03% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits prostaglandin synthesis including in the conjunctiva and uvea; structurally and pharmacologically related to ibuprofen.
         When administered prophylactically, ocular flurbiprofen reduces miosis, permitting maintenance of drug-induced mydriasis during
         surgical procedures. Produces no significant effect on IOP.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>An antiinflammatory, nonsteroidal analgesic. Also inhibits migration of leukocytes into inflamed tissues, depresses monocyte
         function, and may inhibit platelet aggregation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Inhibition of intraoperative miosis; arthritis and other inflammatory diseases; mild to moderate pain.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Management of postoperative ocular inflammation, prevention of postcystoid macular edema.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Epithelial herpes simplex keratitis. Safety during pregnancy (category C), lactation, or in children is not established. For
         contraindications to oral use, see ibuprofen.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concomitant use with other <small>NSAID</small>s; patient who may be adversely affected by prolonged bleeding time; patient in whom asthma, rhinitis, or urticaria is precipitated
         by aspirin or other <small>NSAID</small>s.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Inflammatory Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200300 mg/d in 24 divided doses (max: 300 mg/d)<br/><br/><span class="indicationtitle">Mild-to-Moderate Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg q68h<br/><br/><span class="indicationtitle">Inhibition of Intraoperative Miosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> 1 drop in eye approximately q30min beginning 2 h before surgery for a total of 4 drops per affected eye<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Instill ophthalmic preparation with great care to avoid contamination of solution. Do not touch eye surface with dropper.</li>
</ul><span class="adminroutetype">Oral</span><br/><ul>
<li>Use the 300 mg dose for initiation of therapy or for acute exacerbations of disease.</li>
<li>Store at 15°30° C (59°86° F) in tight, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Special Senses:</span> <span class="speceff-common">Mild ocular stinging,</span> burning, itching, or foreign body sensation (transient). <span class="typehead">Other:</span> Slowed corneal healing; increased bleeding time. <b>For adverse effects to oral preparations, see ibuprofen.</b>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">oral anticoagulants</span>, <b>heparin</b> may prolong bleeding time; actions and side effects of both flurbiprofen and <b>phenytoin,</b> <span class="classification">sulfonylureas</span>, or <span class="classification">sulfonamides</span> may be potentiated. <span class="typehead">Herbal:</span> <b>Feverfew,</b> <b>garlic,</b> <b>ginger,</b> <b>gingko</b> may increase bleeding potential. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 80% absorbed from GI tract. <span class="typehead">Onset:</span> 2 h. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Duration:</span> 68 h. <span class="typehead">Distribution:</span> Small amounts distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine; some biliary excretion. <span class="typehead">Half-Life:</span> 5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe patients with history of cardiac decompensation closely for evidence of fluid retention and edema.</li>
<li>Lab tests: Baseline and periodic evaluations of Hgb, renal and hepatic function, and auditory and ophthalmologic examinations
            are recommended in patients receiving prolonged or high-dose therapy.
         </li>
<li>Monitor for GI distress and S&amp;S of GI bleeding.</li>
<li> 							Note: Symptoms of acute toxicity in children include apnea, cyanosis, response only to painful stimuli, dizziness, and nystagmus. 						</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report ocular irritation that persists after flurbiprofen use during surgery (tearing, dry eye sensation, dull eye pain, photophobia)
            to physician.
         </li>
<li>Be alert for bleeding tendency and report unexplained bleeding, prolongation of bleeding time, or bruises. Minor systemic
            absorption may temporarily increase bleeding time.
         </li>
<li>Notify physician immediately of passage of dark tarry stools, "coffee ground" emesis, frankly bloody emesis, or other
            GI distress, as well as blood or protein in urine, and onset of skin rash, pruritus, jaundice.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to the drug is known.</li>
<li>Do not self-medicate with OTC drugs without consulting physician.</li>
<li>Avoid alcohol and <small>NSAID</small>s unless otherwise advised by physician. Concurrent use may increase risk of GI ulceration and bleeding tendencies.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>